Search results for "REF"

Evaluation of Safety, Tolerability and Efficacy of Temsirolimus in Patients with Relapsed or Refractory Mantle Cell Lymphoma (Rel/Refr Mcl) in Routin…

2014

ABSTRACT Aim: Temsirolimus (TEMS), an mTOR-inhibitor, is approved in the EU for the treatment of patients (pts) with relapsed or refractory (rel/refr) MCL. A pivotal study demonstrated significantly longer progression free survival with TEMS (175 mg weekly for 3 weeks followed by 75 mg weekly) in rel/refr MCL pts compared to investigatoŕs choice therapy (4.8 mo vs 1.9 mo; P = .0009). To evaluate safety and efficacy of TEMS in an unselected patient population during clinical routine, a prospective non-interventional study with TEMS in rel/refr MCL pts is useful. Here we report on interim results of the study. Methods: A German multicenter registry for rel/refr MCL pts treated with TEMS was s…

Randomized Comparison of Sequential High-Dose Cytosine Arabinoside and Idarubicin (S-HAI) with or without Chemo-Modulation by Fludarabine in Refracto…

2001

In order to assess the value of the addition of fludarabine as a chemo-modulator to a high-dose AraC based salvage regimen for patients with refractory and relapsed acute myeloid leukemia the German AML Cooperative Group initiated a prospective randomized comparison between fludarabine q 12 hours on days 1,2,8, and 9 in addition to the S-HAI regimen, consisting of high-dose AraC q 12 hours on days 1, 2, 8, and 9 and idarubicin on days 3,4,10, and 11, as compared with S-HAI alone. Ninety-one patients have entered the ongoing study, 66 of whom are fully evaluable at the present time (median age 54 years, range 20-75). Twentyfive patients had refractory disease or early relapses, 39 patients h…

When to use frovatriptan in migraine? A reply

2011

Dear Sir, We read with interest the comments of Dr. Tfelt-Hansen [1] on the two recently published randomized controlled trials comparing patients’ preference (primary end-point) and efficacy (secondary end-points) of frovatriptan with respect to rizatriptan [2] and almotriptan [3]. In both studies, frovatriptan showed similar preference and short-term efficacy outcomes (pain relief and pain free episodes at 2 h) with respect to the other two triptans. The principal concern of Dr. Tfelt-Hansen was the very early use of frovatriptan in these studies, making their results hardly comparable with those of previous randomized controlled trials [4–6], where patients waited until the headache was …

Pathway CH-1 Study: Sphenopalatine Ganglion (SPG) Stimulation for Acute Treatment of Chronic Cluster Headache (CCH) - Initial Experience (S36.002)

2012

Objective: We aimed to investigate the safety and efficacy of SPG stimulation for the acute treatment of CCH. Background The pain and autonomic symptoms of cluster headache result from activation of the trigeminal parasympathetic reflex, mediated through the SPG. Design/Methods: A multi-center, dose range finding, multiple headache attack (HA), acute treatment study with random insertion of placebo has been initiated. All subjects meet the ICHD-II criteria for CCH with a minimum of 4 HAs/week. Subjects are implanted with a miniaturized neurostimulator which, along with a controller, provides SPG stimulation. Prior to the randomized period, stimulation parameters are adjusted in a titration …

Unsupervised Numerical Characterization in Determining the Borders of Malignant Skin Tumors from Spectral Imagery

2021

For accurate removal of malignant skin tumors, it is crucial to assure the complete removal of the lesions. In the case of certain ill-defined tumors, it is clinically challenging to see the true borders of the tumor. In this paper, we introduce several computationally efficient approaches based on spectral imaging to guide clinicians in delineating tumor borders. First, we present algorithms that can be used effectively with simulated skin reflectance data. By using simulated data, we gain detailed information about the sensitivity of the different approaches and how variables defined by algorithms act in the skin model. Second, we demonstrate the performance of the algorithms with spectra…

Managing Resistant Hypertension: Not Just a Question of Numbers

2005

Preliminary study of the neuromuscular activation during barefoot and shod running

2015

El objetivo del presente estudio preliminar fue comparar la actividad muscular de los músculos tibial anterior, peroneo lateral largo, gastrocnemio medial y gastrocnemio lateral entre la carrera con y sin calzado, y la influencia de la fatiga. 7 participantes realizaron una carrera de fatiga de 20 minutos al 75% de su velocidad aeróbica máxima en cinta con 1% de pendiente. Se midió la actividad mioeléctrica de los músculos antes mencionados tanto antes como después de la prueba de fatiga en dos condiciones: con calzado y sin calzado. Los resultados mostraron una mayor actividad del tibial anterior durante la carrera en fatiga descalzo respecto a la carrera calzado y una mayor actividad del …

Main Topics

2012

Ösophagusresektion bei unspezifischer Motilitätsstörung der Speiseröhre - Bedeutung der neuropathologischen Befunde

2005

A 47-year-old patient presented with a history of dysphagia for solid food for almost 10 years and weight loss of more than 50 kg. Non-resecting surgical as well as endoscopic procedures (laparoscopic cardiomyotomy with secondary antireflux operations, balloon dilation, Botulinum-toxin injection) were without success. A barium esophagogram showed a confinement of the distal esophagus with a filiform passage of the contrast medium and undigested food in the prestenotic dilated esophageal corpus. Manometry displayed a hypertensive lower esophageal sphincter with a resting pressure of 43.8 mmHg - although completely relaxing. The tubular esophagus was aperistaltic with 100 % simultaneous and r…

Potential options to optimize therapy of gastroesophageal reflux disease with proton pump inhibitors.

2007

Proton pump inhibitors (PPIs) are antisecretory agents that are widely used in the short- and long-term management of gastroesophageal reflux disease (GERD) to relieve symptoms, heal esophagitis, and prevent complications, such as strictures and Barrett’s esophagus. The total healthcare costs of GERD are high, especially for maintenance treatment. Therefore, the choice of cost-effective therapeutic options is an ineluctable challenge for public health authorities, third-party payers, and patients. In some European Union countries, a recent trend of public health authorities is to promote the choice of less expensive PPIs, regardless of their antisecretory potency – this in spite of the evid…